Krakow, Poland – July 19, 2021 – Selvita, one of the largest preclinical contract research organizations in Europe, announced today the appointment of Dean Bornilla, to the role of Vice President of Sales, Head of North America.

Mr. Bornilla will be responsible for a wide scope of corporate and business development activities across North America, including developing and maintaining relationships with key strategic clients, alliance management, and strategic positioning of the Company.

“I am excited to join Selvita to collaborate with very talented and dedicated scientific teams in the field of drug discovery and development. I look forward to expanding Selvita’s exposure and footprint throughout North America to strengthen Selvita’s position as a strategic partner for pharmaceutical and biotech companies,” comments Dean Bornilla, Vice President of Sales, Head of North America at Selvita.

“We are very pleased to welcome Dean as part of our Selvita team. He brings in a wealth of business development experience, market understanding and strategic vision that I am certain will be of a great value to our company. I am excited to have Dean joining the team to expand Selvita’s presence on the North American market,” – comments Milosz Gruca, PhD, Executive Vice President at Selvita.

Dean Bornilla brings in over 20 years of professional experience in the pharmaceutical industry. He has been involved in the commercial launch of seven FDA approved products in the hospital and clinical setting. In 2013, he joined Curia (formerly AMRI) as Director of Business Development for Curia’s Drug Discovery platform. During his 8-year tenure at Curia, Mr. Bornilla has held positions of increasing responsibility with Curia’s API Manufacturing and Drug Product platforms, and most recently with the Drug Discovery and Development group as Vice President of Business Development, Western US/Canada & Asia Pacific. Prior to Curia, Mr. Bornilla held various positions of increasing responsibility in commercial operations at Organon (acquired by Schering-Plough and now Merck) and Forest Laboratories (now Allergan).

Dean Bornilla earned his B.Sc. in Health Sciences from the University of Nevada – Reno.